Biotech Archives - Page 15 of 795

1 minute read

Johnson & Johnson’s Late-Breaking Results From Its PALOMA-2 Study Of Subcutaneous Amivantamab In Combination With Lazertinib Show Clinically Meaningful Antitumor Response And Improved Safety Profile In Patients With EGFR-Mutated Non-Small Cell Lung Can…

June 3, 2:33 PM

administration in new Phase 2 dataCHICAGO, June 3, 2024 /PRNewswire/ -- Johnson & Johnson announced today new data from the Phase 2 PALOMA-2 study evaluating subcutaneous (SC) amivantamab combined with lazertinib as

JNJ

2 minute read

Why Is German Biotech Affimed Stock Soaring On Monday?

By Vandana Singh

June 3, 2:13 PM

Affimed shares surged after positive updates from the AFM24-102 study in NSCLC. The study reported a 71% disease control rate and significant clinical activity, highlighting potential efficacy of AFM24 with atezolizumab.

AFMD

2 minute read

Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect

By Vandana Singh

June 3, 2:05 PM

QurAlis has entered an exclusive license agreement with Eli Lilly for QRL-204, an antisense oligonucleotide for ALS and other neurodegenerative diseases. QurAlis will receive $45 million upfront, with potential milestones and royalties up to $577 million.

LLY

2 minute read

Why Is Arrowhead Pharmaceuticals Stock Trading Higher On Monday?

By Vandana Singh

June 3, 1:55 PM

Arrowhead Pharmaceuticals announced Phase 3 PALISADE study results showing significant triglyceride reduction in familial chylomicronemia syndrome patients treated with plozasiran.

ARWR

2 minute read

Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday

By Vandana Singh

June 3, 12:51 PM

Bristol Myers Squibb's KRYSTAL-12 study reveals Krazati's significant benefits over chemotherapy for KRASG12C-mutated NSCLC, improving progression-free survival and response rates.

BMY

1 minute read

OS Therapies Announces Clinical Update From Ongoing Phase 2b Clinical Trial Of Its Immunotherapy OST-HER2 (OST31-154) In Patients With Resected, Recurrent Osteosarcoma

By Benzinga Newsdesk

June 3, 12:46 PM

1-year Event Free Survival (EFS) of 32.5% vs. 20% 1-year EFS for comparatorInterim 1-year and 18-month Overall Survival (OS) of 90.4%0 Grade 3, 4 or 5 Treatment-related Adverse Events (AEs)41 patient trial fully

OSTX

1 minute read

QurAlis Grants Lilly Exclusive Global License For QRL-204, A Precision Therapy That Restores UNC13A Function In ALS And FTD

By Benzinga Newsdesk

June 3, 12:35 PM

QRL-204 is a splice-switching ASO generated through QurAlis' FlexASO™ Platform; represents Lilly's first program targeting UNC13A in ALS and FTDParties to also collaborate to leverage QurAlis' ALS and ASO

LLY

2 minute read

Why Is Agios Pharmaceuticals Stock Trading Higher On Monday?

By Vandana Singh

June 3, 12:11 PM

Agios Pharmaceuticals shares rose after it announced its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia achieved the primary endpoint of transfusion reduction response.

AGIO

1 minute read

Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024

By Benzinga Newsdesk

June 3, 12:02 PM

First Scientific Presentation of PATHFNDR-2 Acromegaly Safety and Efficacy Data Following Positive Topline Announcement, Showing Rapid and Sustained IGF-1 Responses in People Treated with Paltusotine New PATHFNDR-1

CRNX

2 minute read

Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients

By Vandana Singh

June 3, 12:01 PM

JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile.

JNJ